Steven Kahn
@sekahn.bsky.social
"Just some of the triumphs that have come from our robust biomedical research enterprise. NIDDK, as a reflection of work done across the entire NIH, is a prime example of government monies well spent" The 75th anniversary of #NIDDK #NIH diabetesjournals.org/care/article...
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its Longevity
Steven E. Kahn, Cheryl A.M. Anderson, John B. Buse, Elizabeth Selvin, David A. D’Alessio; NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its Lon
diabetesjournals.org
April 25, 2025 at 1:12 AM
The American Diabetes Association issues an important statement on compounded injectable weight loss medications. diabetesjournals.org/care/article...
Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association
The use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (GIP/GLP-1 RA) clas
diabetesjournals.org
December 4, 2024 at 5:53 AM
The American Diabetes Association issues an important statement on compounded injectable weight loss medications. diabetesjournals.org/care/article...